Parradee Kietsirikul
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) is studying its strategic options, including a potential sale.
The pharmaceutical company is talking with advisers to see if there’s interest, according to a Bloomberg report late Thursday, which cited people familiar with the matter. Jazz (JAZZ) is also looking at options that may include a breakup or the sale of parts of its business.
Jazz Pharma (JAZZ) is looking into the possibility of separating its cannabinoid business from its oncology operations, according to the report. Jazz could see interest from large drugmakers that want to grow in neuroscience and oncology.
Jazz Pharma has a market cap of $8.4 billlion.
Jazz Pharma (JAZZ) declined to comment to Bloomberg.
